Overview

Pilot Study of Preoperative Tarceva (Erlotinib) for Stages I/II Non-Small Cell Lung Cancer

Status:
Completed
Trial end date:
2011-08-01
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to see if Tarceva® (erlotinib) is effective in shrinking tumors. A high resolution CT scan (CT scanner that can view 3 dimensional images of the tumor) will be used to measure the tumor before and after treatment with Tarceva®(erlotinib) . This type of CT scan will measure the tumor by volume and by standard measurement (length and width). Both methods will be compared to find out whether standard measurement or measurement by tumor volume is more accurate.
Phase:
Phase 2
Details
Lead Sponsor:
Weill Medical College of Cornell University
Collaborator:
OSI Pharmaceuticals
Treatments:
Erlotinib Hydrochloride